van der Heijde D, Gladman DD, FitzGerald O, et al. - Researchers investigated how baseline risk factors influence radiographic progression in patients with active psoriatic arthritis (PsA) who had an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARD) and were treated with tofacitinib or adalimumab (ADA). In OPAL Broaden, a 12-month, double-blind phase III trial, tofacitinib 5 mg twice daily (BID; n = 107), tofacitinib 10 mg BID (n = 104), or ADA 40 mg once every 2 weeks (n = 106), was administered to patients, all with 1 background csDMARD. They used the van der Heijde-modified total Sharp score (mTSS) for PsA to score radiographs (baseline and Month 12). At Month 12, all radiographic nonprogression criteria were met in > 90% of patients receiving tofacitinib or ADA. An increase from baseline in mTSS ≤ 0.5, ≤ 0, or ≤ 0.66 defined radiographic nonprogression. Observations revealed greater structural progression in correlation with elevated C-reactive protein levels at baseline. Regardless of C-reactive protein levels, minimal changes in radiographic outcomes were observed.